Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cevira
- Development stage
- Phase 3
- Lead developer
- Asieris Pharmaceuticals
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Vaginal, Topical
01
Overview
Cevira (APL-1702) is a first-in-class, non-surgical photodynamic drug-device combination product developed for the treatment of high-grade squamous intraepithelial lesions (HSIL) of the cervix, including all human papillomavirus (HPV) subtypes. The therapy consists of a photosensitizer applied locally to the cervix and activated by a light source integrated into the device. Upon activation, reactive oxygen species are generated that selectively destroy abnormal cervical cells while sparing healthy tissue. This approach aims to provide an effective alternative to surgical excision procedures such as LEEP or conization, reducing risks like bleeding, infection, scarring, infertility, and pregnancy complications. Phase III clinical trials have demonstrated significant efficacy in histological regression and HPV clearance with good safety outcomes[1][3][5][6]. The product is intended for gynecologist placement and patient removal without disrupting daily activities.
- Brand names
- Cevira
- Other names
- APL-1702APL1702APL 1702Cevira
Beyond the preview
Go deeper on Cevira.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cevira.